STAT

Do Elon Musk’s brain-decoding implants have potential? Experts say they just might

Do Elon Musk’s brain-decoding implants have potential? Independent experts consulted by STAT say they very well might.

SAN FRANCISCO — Okay, the “sewing machine” is pretty cool. But if the device that Elon Musk’s neurotechnology startup Neuralink developed to implant thousands of electrodes into brains (of rats and monkeys so far, and humans eventually) were its only accomplishment, Tuesday night’s big reveal would have been a big meh. Instead, six independent experts in the kind of brain-computer interfaces that Neuralink is developing told STAT they are impressed for the most part, though caveats abound.

“Overall, the concept is impressive and so is the progress they’ve made,” said neurobiologist Andrew Schwartz of the University of Pittsburgh Medical Center, a pioneer in the technology. “But a lot of this still seems to be conceptual. It’s hard to tell what’s aspirational and what they’ve actually done.”

The immediate aim of the San Francisco startup is a system enabling people who are paralyzed to use their thoughts to operate computers and smartphones. That has been done before, including by Schwartz’s group and one at Brown University, where in 2011 two tetraplegic patients who had been implanted with the “BrainGate” neural

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A 486% Drug Price Hike, AstraZeneca CEO Pay, And More
Is there any circumstance when a 486% increase for a medicine might be justified? A small company called Harrow argues the case for an injectable eye treatment.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks